DSCM
REGN icon

Del-Sette Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Del-Sette Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,919
Closed -$2.25M – 53
2025
Q4 		$2.25M Buy
+2,919
New +$1.98M 1.39% 25

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Del-Sette Capital Management's REGN Position: Q1 2026 in Review

Del-Sette Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 2,919 shares — an estimated $2.25M sold.

Del-Sette Capital Management first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $2.25M in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Del-Sette Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Del-Sette Capital Management sold 2,919 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.25M.
  • Del-Sette Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Del-Sette Capital Management's Regeneron Pharmaceuticals position peaked at $2.25M in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Del-Sette Capital Management's 13F filing for Q1 2026, filed 4 May 2026.